Pathfinder Cell Therapy, Inc. (PFND) Stock
Pathfinder Cell Therapy, Inc. is an emerging biotechnology firm specializing in regenerative medicine.
Valuation
Financials & Margins
Annual Financials (USD)
Balance Sheet (USD)
Cash Flow (USD)
Valuation & Return Ratios
Peer Comparison
About Pathfinder Cell Therapy, Inc.
Pathfinder Cell Therapy, Inc. is an emerging biotechnology firm specializing in regenerative medicine. This company is dedicated to pioneering innovative cell-based and associated treatments designed to address a range of illnesses and health issues, particularly those involving localized cellular injury within organs. Its proprietary technology shows promise for tackling conditions such as diabetes, kidney disease, heart attacks (myocardial infarction), and peripheral vascular ailments, among others. Established in 2008, the company maintains its corporate headquarters in Cambridge, Massachusetts.
Pathfinder Cell Therapy, Inc. (PFND) stock trades at $0.00 with a market capitalization of $66716. The stock is valued at a price-to-earnings (P/E) ratio of -0.04, price-to-book of -0.01, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $0.00 and $0.00, and currently trades —% below its 52-week high.
On profitability, Pathfinder Cell Therapy, Inc. generates a return on equity (ROE) of 33.33% — well above the market average, a sign of a high-quality business, return on capital employed of 18.83%, an operating margin of 0.00%, a net profit margin of 0.00%.
Official website: www.pathfindercelltherapy.com